Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Decreases By 59.6%

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 533,000 shares, a decline of 59.6% from the March 31st total of 1,320,000 shares. Approximately 6.1% of the company’s shares are short sold. Based on an average daily trading volume, of 946,600 shares, the short-interest ratio is presently 0.6 days.

ABVC BioPharma Stock Performance

ABVC opened at $1.59 on Friday. ABVC BioPharma has a one year low of $0.67 and a one year high of $9.60. The stock has a market cap of $16.79 million, a price-to-earnings ratio of -0.65 and a beta of 0.75. The stock’s 50 day moving average price is $1.21 and its 200-day moving average price is $1.25.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.35) EPS for the quarter. ABVC BioPharma had a negative net margin of 6,919.08% and a negative return on equity of 226.65%.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.